Fulvestrant

目录号:S1191 别名: ICI-182780, ZD 9238

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant是一种Estrogen receptor(ER)拮抗剂, 无细胞试验中IC50为0.094 nM。

规格 价格 库存 购买数量  
RMB 533.25 现货
RMB 567.34 现货
RMB 2233.34 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • PTPH1 confers breast cancer cell sensitivity to fulvestrant. E and F, PTPH1 overexpression increases the growth inhibition by fulvestrant. PTPH1 was overexpressed by a Tet-on system or a stable transfection, and resultant cells were incubated with fulvestrant as indicated for about 2 weeks. Colony formed was stained and counted. Results shown are normalized to its own solvent control of Vector and PTPH1-overexpressed cells, respectively (means ± SD; n = 3–5) with insets showing PTPH1 overexpression. *, versus vector or no Tet cells for E and F.

    Mol Cancer Ther 2014 13(1), 230-8. Fulvestrant purchased from Selleck.

     

    Fulvestrant resistance induced by 6 different ZF-TFs. (A) Drug sensitivity of fulvestrant-selected MCF7 ZF-TF-transduced cells. MCF7 cells transduced with one of six different ZF-TF-expressing retroviruses selected first in puromycin (the transduction selection marker) and then in fulvestrant for 1 month were grown in the absence of fulvestrant for 7 days and then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for 21 days followed by crystal violet staining and visualization. Data are representative of triplicate experiments.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

  • Fulvestrant resistance induced by 6 different ZF-TFs. (B and C) Growth curves of MCF7 and T47D cells in the presence and absence of fulvestrant. Comparison of cell growth rates (cell number, mean +/2 SEM, n = 8; time in days as indicated) of MCF7 and T47D cells stably transduced with control retrovirus or one of six different ZF-TF-expressing retroviruses (7, 19, 64, 70, 83 and 115) in the presence (blue line) or absence (pink line) of fulvestrant.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

    CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments. (c) MCF-7 and MR cells were treated with different concentrations of ICI, collected after 24 h and then immunoblotted with the indicated antibodies.

    Oncogene, 2016. Fulvestrant purchased from Selleck.

  • A: Time dependent loss of MGMT activity in ERα-positive MCF7 and T47D tumor cells but not in ERα-negative MDAMB-468 cells after 1 μmol/L Fulvestrant treatment (upper panel). Concentration dependent inhibition of MGMT activity in MCF7 and T47D cells but not in MDA-MB-468 cells after a 72 hours exposure to fulvestrant (lower panel). The data represents the mean of two independent experiments in duplicate and the last time point (72 hours) as assessed by student's t-test was significant at P < 0.05. B: Decreased MGMT and ER-α protein levels in MCF7 cells after 48 hours and 72 hours fulvestrant exposure. ICI is fulvestrant, also called ICI-182,780. C: Decreased MGMT and ER-α protein levels in T47D cells after 48 hours and 72 hours fulvestrant exposure.

    J Biomed Res, 2016, 30(5):393-410. Fulvestrant purchased from Selleck.

产品安全说明书

Estrogen/progestogen Receptor抑制剂选择性比较

生物活性

产品描述 Fulvestrant是一种Estrogen receptor(ER)拮抗剂, 无细胞试验中IC50为0.094 nM。
靶点
ER [1]
(Cell-free assay)
0.94 nM
体外研究

Fulvestrant 有效抑制ER阳性的MCF-7生长(IC50为 0.29 nM),而对ER阴性的的 BT-20人类乳腺癌细胞的生长没有作用效果。Fulvestrant 使细胞在 G0/G1 期累积,也降低了能持续进行DNA合成的细胞比例。[1] Fulvestrant 竞争性地抑制雌二醇与雌激素受体结合。 Fulvestrant通过损害受体二聚化和能量依赖型核质转运,而阻断ER的核定位。由于Fulvestrant-ER复合体的不稳定性,Fulvestrant与ER的结合最终会导致 ER蛋白的加速退化。[2] Fulvestrant (10 nM) 不仅可降低IGF-IR mRNA水平,也降低半衰期。[3] 100 μM Fulvestrant 处理MCF-7细胞,提高TNFR1 和TRADD 稳态的mRNA水平,这种作用具有时间依赖性。[4] Fulvestrant 作用于LNCaP人类前列腺癌细胞,可以下调雄激素受体的表达,也减少雄激素的反应。Fulvestrant也显著降低R1881 刺激的生长,降低 70%。[5]Fulvestrant作用于未成熟的小脑神经元,通过快速激活MAPK,可以调节有丝分裂和细胞死亡。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC3NW9GOS5|LUGwNFAhdk1? MmTZOFghcA>? M2rKPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIm1WowzPDl5OUK5OC=>
MCF-7/LTED M1HF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrQWngyNjNvMUCwNEBvVQ>? NVn5[WRTPDhiaB?= MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFnvN4wzPDl5OUK5OC=>
HCC1428 M3vE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOxMlMuOTByMDDuUS=> M2G0WlQ5KGh? M{nPWIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkXwNlQ6Pzl{OUS=
HCC1428/LTED M3ntWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvtNU4{NTFyMECgcm0> M4PNdVQ5KGh? NGH0S45qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NEn0ZlQzPDl5OUK5OC=>
LCC1 MWXGeY5kfGmxbjDBd5NigQ>? NUD3TY0yOTByIH7N NEP4Zog1QC1zNESgbC=> NGL3SJpi[3SrdnH0[ZMhXVCUIIPp[45idGmwZx?= NIfhVXEzPDh3OEK3Oy=>
LCC9 MXHGeY5kfGmxbjDBd5NigQ>? MUixNFAhdk1? M{fQN|Q5NTF2NDDo M4DHWIFkfGm4YYTld{BWWFJic3nncoFtcW6p M2j4TlI1QDV6Mke3
MCF-7  NX\lcIZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBNVAxKG6P MmrIOUBl MVHpcohq[mm2czDj[YxtKGe{b4f0bEB1dyBzMP-8iS=> MljaNlQ5OTl3NUC=
mesangial  M4DNTmZ2dmO2aX;uJGF{e2G7 NHL5VHExNjFvMUCwJI5O M3TuOFQ5KGh? Mnm2d5VxeHKnc4Pld{BVT0ZvzsKxMYlv\HWlZXSgeJlx\SCLVjDjc4xt[Wenbh?= MXyyOFc6OzZ|OR?=
Mesangial NGCwbI9HfW6ldHnvckBCe3OjeR?= M2qyN|AvOS1zMECgcm0> NVzCeFVoOC53IHi= M37Fb4lvcGmkaYTzJHRITi4QskGtbY5lfWOnZDDTcYFlOiCyaH;zdIhwenmuYYTpc44hfmmjIFfQSXI> MXmyOFc6OzZ|OR?=
ER+ MCF-7/2a M3zGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMEC0JO69VQ>? NILjS3YyPTN{NEi4OC=>
ER+ MCF-7 NYTaWm06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PPZ|IxOCCq MlzmTWM2OD1yLkKxJI5O MVKxOVMzPDh6NB?=
MCF-7  M37XWmZ2dmO2aX;uJGF{e2G7 M2PT[|ExyqCwTdMg NV3lbnIzPzJiaB?= M4TqOZJmfmW{c3XzJJRp\SCnc4Tyc4dmdiCnZn\lZ5QpUUN3MDCxMlkhy5diMUFijLI6KE1r NE\jOJUzPDlyOE[1Ni=>
MCF-7  MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17kc2lEPTEEoH;mJIFxeHKxeHntZZRmdHliMjDuUS=> NXTCPG1TOjN2NEizOFY>
H1975  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;LeFPDqM7:TR?= NEDiO4EyKG1? NUTHbHFJcW6lcnXhd4V{KHSqZTDn[YZqfGmwaXKgd4Vve2m2aY\peJkhd2ZiSEG5O|Uh[2WubIRCpC=> MVyyOFI3QDhzMB?=
H1975 NIG0U2xHfW6ldHnvckBCe3OjeR?= M4fsO|PDqM7:TR?= MXyxJI0> MXv1dJJm\3WuYYTld{B1cGVibHX2[Ywhd2ZiTHX0MVdk MY[yOFI3QDhzMB?=
MCF-7  NVj3OoFXTnWwY4Tpc44hSXO|YYm= MYexNFDjiImwTdMg M176[VczKGh? M3X1WZJmfmW{c3XzJJRp\SCycn;0[YN1cX[nIHXm[oVkfCCxZjDFNuKhcW5iY3XscEBqdn[jc3nvci=> MUSyN|k{Pjd5Mx?=
MCF-7  MWXGeY5kfGmxbjDBd5NigQ>? MlXrNVAx6oDLbl5CpC=> NWjid25UOjRxNEigbC=> M2PLbIZi[2muaYTheIV{KGmwdnHzbY9vKHSqcn;1[4ghVU2SczegcY9lfWyjdHnvci=> MmLRNlM6OzZ5N{O=
BT474-tet-shMED1 M4rMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L1R|AvOS13IN88US=> NXzpWnFEPyCm NHTVfFFqdmO{ZXHz[ZMhM0SxeDDpcoR2[2WmIHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmTlNlM6OzZ{M{S=
ZR75-1-tet-shMED1  NYi4T3BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjNZVUxNjFvNTFOwG0> MYi3JIQ> M2S2[4lv[3KnYYPld{AsTG:6IHnu[JVk\WRiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUXIZWdDOjN7M{[yN|Q>
MCF-7-tet-shMED1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfVfVMzOC5zLUWg{txO M1;LeVch\A>? NFmyPYJqdmO{ZXHz[ZMhM0SxeDDpcoR2[2WmIHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NILmSI4zOzl|NkKzOC=>
HepG2  Mlf6SpVv[3Srb36gRZN{[Xl? NECzdmkxNjBzLUGwJO69VQ>? MljuNVghcMLi MVHhZ5RqfmG2ZYOgeIhmKEWURT3t[YRq[XSnZDD0doFve2O{aYD0bY9vKG:oIFHGNmVT M4LW[lI{PzN|MUi4
MCF-7L  MWDGeY5kfGmxbjDBd5NigQ>? MXyxNFAhdk4EoB?= NVXiVpRGOTBibXnuM|I1KGhxNEigbC=> M3TXUJJme3WudIOgbY4hTUeIUjygTGVTOiCjbnSgTGVTOyCyaH;zdIhwenmuYYTpc44h[XRicILvcI9v\2WmIHX4dI9{fXKn MofRNlM3QDZ2MU[=
MCF-7L  M4XTVWZ2dmO2aX;uJGF{e2G7 MlvKNVAxKG6PwrC= NXfZbVNUPDhiaB?= NUjKUY41cW6mdXPld{B2eHKnZ4XsZZRqd25ib3[gcXJPSSCxZjDFS2ZTKGyrZ3Hu[EBJSi2HR1[= MV2yN|Y5PjRzNh?=
MCF-7L MUnGeY5kfGmxbjDBd5NigQ>? NXi5R5F[OTByIH7NxsA> MoL5OFghcA>? NFrRTJJqdmS3Y3XzJGVITlJiZnHtbYx6KG2nbXLldkBi[3SrdnH0bY9vKHKncYXpdoVlKEWU MnPiNlM3QDZ2MU[=
C4-12  NUDE[YVTTnWwY4Tpc44hSXO|YYm= NG\uSlMyODBibl5CpC=> NI\ab|k1QCCq M3HEPYlv\HWlZYOgSWdHWiCoYX3pcJkhdWWvYnXyJIFkfGm4YYTpc44hemWzdXny[YQhTVJ? NIPrNmYzOzZ6NkSxOi=>
MCF-7L M4PadWZ2dmO2aX;uJGF{e2G7 NU\udpRXOTByIH7NxsA> MmO5NlQhcA>? MXPpcoR2[2W|IFXHSnIheGixc4Doc5J6dGG2aX;uJJJmeXWrcnXkJGhDNUWJRjDmeY5kfGmxbh?= MkjhNlM3QDZ2MU[=
MMQ  M1yyfmZ2dmO2aX;uJGF{e2G7 MVOwMVYzPSCwTR?= NEXnRYc4OiCq NEfhNnZld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDld5Rzd2enbjDy[YNmeHSxcj5OtUApTVMQsTm= M2fKNlI{PTJ|M{W3
H1975  M4X0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGwMlMyOjVvMUCg{txO Mn\mOkBl MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXGyN|M6QTl3Nx?=
H1975  M3nxd2Fxd3C2b4Ppd{BCe3OjeR?= NEPZ[YYzODBibl2= NGHFRo84OiCq M1nXPYVvcGGwY3XzJIVzdG:2aX7pZkBqdmS3Y3XkJIFxd3C2b4Ppdy=> M4TRN|I{Ozl7OUW3
MCF-7  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluxNVAwOTByL{GwNFAhdk1? NXrXS4xSOi92L{[g[C=> M4nqXGROW09? Mnz1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= MlmzNlM{OTN3ME[=
MCF-7  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOxNFAhdk1? MV20JIQ> MnrSSG1UVw>? NXj6NGdPcW6mdXPld{BiKGirZ3jldkBxem:yb4L0bY9vKG:oIHPlcIx{KGmwIITo[UBIOSCyaHHz[eKh MUGyN|MyOzVyNh?=
MLO-Y4  MnO3SpVv[3Srb36gRZN{[Xl? NFrGRZoyyqEQvF2= NXy3TYFUOSCq NXnHT2xncW6qaXLpeJMhTTJvaX7keYNm\CCFeESzJIV5eHKnc4Ppc44> M{fHWVI{OjR5MEW3
MCF-7 NYPKbZI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknXNVAxKG6P M134N|Q5KGh? NYHlUWhK[WK{b3fheIV{KHSqZTDwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCvb3TldoF1\SCwaYTyc5NifGm4ZTDzeJJme3N? NWLOPZc{OjN{MU[3OFQ>
TG1-1  MUfGeY5kfGmxbjDBd5NigQ>? NVLJUpU4OcLizszN NU[zd2pEOjRiaB?= M2PlN4Fjem:pYYTld{BGOsLiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhUEmILUJOtS=> NHHyTVIzOzB6OE[wOy=>
TG1-1  MV;GeY5kfGmxbjDBd5NigQ>? NETWSoUyyqEQvF2= MW[yOEBp NUjsVZJm[WK{b3fheIV{KEV{wrDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCSSUPL NXf5XHJ5OjNyOEi2NFc>
MCF7 M2PTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXixNFAhdk1? NXLzWXViPDhiaB?= Mm\6cIVi\HNidH:gZUB{cW2rbHHyJIxwe3NiaX6gd5Vzfmm4YXygZZMhf2m2aDDkc5hwenWkaXPpckBidG:wZR?= MXeyN|A4PzJ2OR?=
MCF7 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxNFAhdk1? NWHMT5NCPDhiaB?= M1HlPYVvcGGwY3XzJI52fGyrbj3t[YRq[XSnZDDj[YxtKGSnYYTo NEPpWFczOzB5N{K0PS=>
MCF-7  Ml30SpVv[3Srb36gRZN{[Xl? NFPtZZU3KGh? NXSzbXlETE2VTx?= M3HBOoF1fGWwdXH0[ZMhfGinIH\seYRqd3ixbnnsMUBweiCoZX7o[ZhidWmmLXnu[JVk\WRiaX7jdoVie2ViaX6gcYlTNTJzIHX4dJJme3Orb36= NHvudZEzOzB3MkCzOi=>
MCF-7 MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTh[WtPOTByIH7NM|Eh|ryP NXLhc2lZPSCm MXzpcohq[mm2czD0bIUhe3SrbYXsZZRqd25ib3[gNVfPui2nc4TyZYRqd2x? M1nw[VIzQTh{N{[1
MCF-7 NELOdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNFAhdk1? MmH4OUBl NYLxVXQ6cW6qaXLpeJMhfGinIIP0bY12dGG2aX;uJI9nKG[3c3HybYVtcW5iSB?= M3\qUFIzQTh{N{[1
1471.1 NYLNZY9ITnWwY4Tpc44hSXO|YYm= MWCxNFAhdk1? MmnRNUBp NHrDSGdGfE:KwrC= MW\0ZYtmeyCxbjDhJJB2dmO2YYTlJJN1[WmwaX7nJJBifHSncn6= MVmyNlg3QTFyNh?=
MCF-7 NH7LVJpHfW6ldHnvckBCe3OjeR?= MWWxNFAhdk1? MkXINUBp NF3U[HpGfE:KwrC= MX70ZYtmeyCxbjDhJJB2dmO2YYTlJJN1[WmwaX7nJJBifHSncn6= NXTtO29kOjJ6NkmxNFY>
HeLa MmTVSpVv[3Srb36gRZN{[Xl? MXOxNFAhdk1? NUjYcHFEOSCq NEf0NI1GfE:KwrC= NHrI[Ip1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NH7uSWwzOjh4OUGwOi=>
COS-7  MYHGeY5kfGmxbjDBd5NigQ>? MofYNVAxKG6P NH;DSVEyKGh? MX3FeG9JyqB? M2jvV5Ric2W|IH;uJIEheHWwY4TheIUhe3SjaX7pcocheGG2dHXyci=> MVKyNlg3QTFyNh?=
BG1L-OHTLT  MX3GeY5kfGmxbjDBd5NigQ>? MlnRNVDDqG6P NX:yR3NPOjUEoHlCpC=> MXXpcohq[mm2czDFVu6yKGW6cILld5Nqd25? Mlr2NlI3PTJ3NUi=
BG1L-ICILT NWXWW4Y4TnWwY4Tpc44hSXO|YYm= NX\vZmY1OTEEoH7N NGSycpQzPMLiaNMg MXHpcohq[mm2czDFVu6yKGW6cILld5Nqd25? NGP5bYEzOjZ3MkW1PC=>
PC-9 M2H3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnFNE4xODNvM{Cg{txO MVS0PEBp NUXxTJNbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIKySJYzOjV4ME[zOC=>
H1650 NV\STIZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLhfnRGOC5yMEOtN|Ah|ryP Ml6zOFghcA>? NYLONFFWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NW\YXng{OjJ3NkC2N|Q>
H1975 NFiyd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7tNE4xODNvM{Cg{txO M4H5NFQ5KGh? M1HjWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2jtVlIzPTZyNkO0
H1975 MVTGeY5kfGmxbjDBd5NigQ>? NYHLUXNDO8LizszN NGjtNXc{KGh? M1jEW4Fjem:pYYTld{B1cGVicHjvd5Bpdy2HR1\SJIlv\HWldHnvckBjgSCnc4Tyc4dmdg>? NWjPO3FrOjJ3NkC2N|Q>
H1975 NFrUPZNHfW6ldHnvckBCe3OjeR?= MmnGN:Kh|ryP MX63JIQ> NWjGe2VxcW6mdXPld{BGT0[UIHX4dJJme3Orb36= NIi2[mozOjV4ME[zOC=>
HTR-8 NI\yOFVHfW6ldHnvckBCe3OjeR?= NXnT[YtWOcLizszN MlrTNU01QCCq MWnkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCLR1\CVFchdVKQQR?= NIKxZ44zOjN6M{GxNS=>
JEG-3 Moi1SpVv[3Srb36gRZN{[Xl? NYjuSop7OcLizszN MV2xMVQ5KGh? M{LDV4Rwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyCvUl7B MnnDNlI{QDNzMUG=
Huh7 MYfGeY5kfGmxbjDBd5NigQ>? NUj5V3ZUPTEEoN88US=> NHXOW5U1QCCq NHnCcGJqdmirYnn0d{Bo\W6rc4TlbY4udWWmaXH0[YQhWE:QMTD0doFve2GldHn2ZZRqd25? M4r2V|IzOzB2Mkm2
201T M{fBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSwOUDPxE1? NH7hTpI4OiCq NUnTbphCcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= NIPUeHEzOjJ3OES3Oi=>
A549  Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYq1JO69VQ>? M2\YUlczKGh? M2m1RYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC4YX7k[ZRidmmk NHrmfIUzOjJ3OES3Oi=>
MCF-7 MYfGeY5kfGmxbjDBd5NigQ>? M17ZSFHDqM7:TR?= NV\wRmVGOjRiaNMg NFHsXVhld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc44hcW6mdXPl[EBjgSB2LV;IMXQhyqB? MofPNlIxPDl|MU[=
HCC-1428 MlrXSpVv[3Srb36gRZN{[Xl? NET0WWoyyqEQvF2= NYC2dGtKOjRiaNMg M1r0cIRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KDRvT1itWEDDqA>? MWCyNlA1QTNzNh?=
MDA-361 NH;X[2lHfW6ldHnvckBCe3OjeR?= MmP3NeKh|ryP NGnWTpIzPCCqwrC= NHTTcFdld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc44hcW6mdXPl[EBjgSB2LV;IMXQhyqB? MnT6NlIxPDl|MU[=
ZR75-1 Ml[4SpVv[3Srb36gRZN{[Xl? MnjCNeKh|ryP NULOWlE6OjRiaNMg M3GwUoRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KDRvT1itWEDDqA>? NHr2RZozOjB2OUOxOi=>
MCF-7 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn1dpp3OcLizszN NVTXUlNOPS1zMDDk M2OwOJN2eHC{ZYPz[ZMhTTJvaX7keYNm\CCpcn;3eIghcW6qaXLpeIlwdg>? NW\6NlZnOjJyNEmzNVY>
HCC-1428 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnVbZJQOcLizszN M4O3N|UuOTBiZB?= NVrqUYZYe3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w MoXqNlIxPDl|MU[=
MDA-361 M2\zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TONFHDqM7:TR?= NH;xOoQ2NTFyIHS= Ml\Xd5VxeHKnc4Pld{BGOi2rbnT1Z4VlKGe{b4f0bEBqdmirYnn0bY9v M1\TeFIzODR7M{G2
ZR75-1 NGTVcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxxsDPxE1? NYPCbVFHPS1zMDDk MXnzeZBxemW|c3XzJGUzNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> MmTGNlIxPDl|MU[=
MCF-7/AC-1 MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7wc|VYOC1yLkKg{txO MWW2JIQ> MWrpcohq[mm2czDj[YxtKGe{b4f0bEBud2Snc4TsfS=> NInGXnYzOjB2Mke5Ni=>
MCF7 M4nwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXixNEDDvU1? MXy0PEBp MYjpcoR2[2W|IHPlcIwhcW6qaXLpeIlwdiC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkh\mmkcn;icIF{fHN? M13Q[|IzODRzOEi3
MMQ MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofNNE03OjVibl2= MYe3NkBp MWnwdo9lfWOnczDzeIF1cXO2aXPhcIx6KHOrZ37p[olk[W62IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vyqB? MUOyNlAyPTFyMR?=
MMQ M1TxcWZ2dmO2aX;uJGF{e2G7 NW[3Zop1OC14MkWgcm0> MYq3NkBp NWjCVWdJeHKxZIXj[ZMh[SC|dHH0bZN1cWOjbHz5JJNq\26rZnnjZY51NCCmb4PlMYRmeGWwZHXueEBz\WS3Y4Tpc44hcW5iUGLMJJNm[3KndHnvci=> Mm\pNlIxOTVzMEG=
MCF7 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\PS|AuOSEQvF2= MXqyOE0yOjBiaB?= MoPvbY5pcWKrdIOgeIhmKGe{b4f0bEBw\iCPQ1[3MXlDNTIEoB?= NGmzPHozOTh4M{K1PC=>
HepG2 NHfCZ3pCeG:ydH;zbZMhSXO|YYm= MnLqNE4yyqEQvF2= MlGyNlQhcA>? Mn\0ZYJwdGm|aHXzJJRp\SCnc4Tyc4dmdi2rbnT1Z4VlKHWyLYLl[5Vt[XSrb36gc4Yh[XCxQVmgZY5lKGGyb12= M2DUclIyQDF4MkOz
MCF7–iFR3 NGXhRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj4PXVEOjBvMUCwJI5O NWDhOlJzQTZiaB?= NF\neHZmdmijbnPld{BCWC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= MYGyNVc6Ojh6OR?=
MCF7S NHfaeXZHfW6ldHnvckBCe3OjeR?= M4r5[|HDqM7:TR?= M4rST|Q5KGh? MWnkc5dvemWpdXzheIV{KG:4ZYLhcIwhTVMQsTDwdo91\WmwIHzleoVtew>? NGXucIgzOTV|M{G5OS=>
MCF7 MnrLSpVv[3Srb36gRZN{[Xl? MU[xxsDPxE1? MnLiOFghcA>? NVuwUJZD\G:5boLl[5Vt[XSnczDveoVz[WyuIFXS{tEheHKxdHXpckBt\X[nbIO= M4DkclIyPTN|MUm1
MCF7S NYTad5J4TnWwY4Tpc44hSXO|YYm= NIDoUJQyyqEQvF2= MnLXO{Bl NYjkVJd7[XS2ZX71ZZRmeyC2dX3vdpNxcGW{ZTDmc5Ju[XSrb36gZY5lKHC{b3zp[oVz[XSrb36= NV\t[VNmOjF3M{OxPVU>
MCF7S MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrLV3gxNjVxMTFOwG0> MVm3JIQ> M2jTbGROW09? MnfX[IVkemWjc3XzJINmdGxiZYjwZY5{cW:w M4\tfVIyPTN|MUm1
T47D  MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWG0JI5O MkPKOFAhcA>? MkfVd5VxeHKnc4Pld{Bk\WyuIHfyc5d1cCCvb3TldoF1\Wy7 MofENlE1QDB|OUG=
BT474  NHvMW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnRemc4PCCwTR?= NGLNPJQ1OCCq MUfzeZBxemW|c3XzJINmdGxiZ4Lve5RpKG2xZHXyZZRmdHl? NHrUZ4QzOTR6MEO5NS=>
T47D  M2L1bmZ2dmO2aX;uJGF{e2G7 M33PSFExKG6P MYS0NEBp M1Pub4Rwf26{ZXf1cIF1\XNiRWNOtUBxem:2ZXnu NHjiNpQzOTR6MEO5NS=>
BT474  NVHVfWhwTnWwY4Tpc44hSXO|YYm= M13nflExKG6P NXj0Z2ljPDBiaB?= NWq5R20z\G:5boLl[5Vt[XSnczDFVu6yKHC{b4TlbY4> NVz0W5lJOjF2OECzPVE>
MCF7 MnH0SpVv[3Srb36gRZN{[Xl? M2LPTlExOCCwTR?= M{PONlch\A>? NEf1WXpz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 NXzvXY86OjF|OU[wPVQ>
T47D  NFH0cXFHfW6ldHnvckBCe3OjeR?= MVixNFAhdk1? NIrD[Io4KGR? NFzlNWFz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 M3XJeFIyOzl4MEm0
BT474  M2TQbWZ2dmO2aX;uJGF{e2G7 NGnwRWQyODBibl2= M2jMXVch\A>? Ml7FdoVlfWOnczDFVu6yKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> NV6xU3BROjF|OU[wPVQ>
MDAMB361 MVXGeY5kfGmxbjDBd5NigQ>? NW\rZZNlOTByIH7N M3vTXlch\A>? NHnqSXpz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 M3fvdlIyOzl4MEm0
MCF7 NGrmO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjTNE4xOS1zIN88US=> MV:3JIQ> MVfy[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? MonuNlE{QTZyOUS=
T47D  NX3oPXpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqwMlAyNTFizszN NFvCV5g4KGR? MnrZdoVlfWOnczDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 M3WxVVIyOzl4MEm0
BT474  NV\yUGxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHGNE4xOS1zIN88US=> NE\X[mo4KGR? NXHPNmp7emWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 M4jHWVIyOzl4MEm0
MDAMB361 NH\mOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrCVZBPOC5yMT2xJO69VQ>? NGrSN2U4KGR? NXL0[WFTemWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 MknRNlE{QTZyOUS=
MCF7 MWnGeY5kfGmxbjDBd5NigQ>? NYWxTZJKOTByIH7N M4r4fVch\A>? NX7ifW5TcW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> MVmyNVM6PjB7NB?=
T47D  NUD0W5FQTnWwY4Tpc44hSXO|YYm= M1\INlExOCCwTR?= M2O4UFch\A>? NVv0fXY5cW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> MmrUNlE{QTZyOUS=
BT474  NV3QZYtFTnWwY4Tpc44hSXO|YYm= M{j2UVExOCCwTR?= NFHKV5I4KGR? MXrpcoR2[2W|IH;mJGVz[kJ|IHHu[EBGemKENDDy[YNmeHSxcjDlfJBz\XO|aX;uJIFv\CC|aXfuZYxtcW6p MkDFNlE{QTZyOUS=
MDAMB361 MULGeY5kfGmxbjDBd5NigQ>? NU\YTYFmOTByIH7N MkDXO{Bl NEDFcplqdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n NG\hS2wzOTN7NkC5OC=>
MCF7 MkPMSpVv[3Srb36gRZN{[Xl? NHfkWIUyOCCwTR?= M33sWlk3KGh? MUfkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb39CpC=> Mk\2NlE{Pzh|M{O=
MDA-MB-231 NF7iTXNHfW6ldHnvckBCe3OjeR?= NE\BVVQyOCCwTR?= Mm\5PVYhcA>? MV7kc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb39CpC=> NVnn[GJuOjF|N{izN|M>
SK-BR-3 NEj0TZlHfW6ldHnvckBCe3OjeR?= MWSxNEBvVQ>? M3XBNlk3KGh? Mnqx[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> NGPiUWczOTN5OEOzNy=>
MCF-7 M2TVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPKNVAxKG6P NYPZeJZRPzJxOU[gbC=> NVjSeFBZ[2G3c3XzJINmdGxiY4njcIUh[XK{ZYP0 M122U|IyOjl7OE[y
MMQ NYi2N5o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nHeVAvODB6LU[yOUBvVQ>? M2LjU|czKGh? MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXKyNFcxODd3NR?=
MMQ M1fiZWZ2dmO2aX;uJGF{e2G7 MXWwMlAxQC14MkWgcm0> NInBTYk4OiCq M1n0N4lvcGmkaYTzJHBTVCC|ZXPy[ZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWHV[HhMOjB5MEC3OVU>
MMQ M3\MSWZ2dmO2aX;uJGF{e2G7 Mm[1NE4xPC14MkWgcm0> MmXOO|IhcA>? NYLnSJBTcW6qaXLpeJMhTVMQsTDlfJBz\XO|aX;u M3;nXVIxPzByN{W1
MMQ M4HqUGZ2dmO2aX;uJGF{e2G7 NUjadG9KOC5yND22NlUhdk1? M{TMRVczKGh? MkC3eZBz\We3bHH0[ZMhXEeIzsKzJIFv\CCWR1dOtnJKUSCneIDy[ZN{cW:w M2[xTlIxPzByN{W1

... Click to View More Cell Line Experimental Data

体内研究 Fulvestrant缺乏子宫活性,与雌二醇联用皮下注射给药未成熟的雌性大鼠,有效抑制雌二醇的子宫内活性,ED50 为0.06 mg/kg/day。5 mg Fulvestrant悬浮液皮下注射到MCF-7移植瘤中,完全抑制肿瘤生长。10 μM Fulvestrant也有效抑制BrlO人类乳腺癌移植瘤的生长。[1] Fulvestrant (10 mg/rat) 皮下注射到大鼠前列腺腹侧,降低雄激素受体的表达,ERK1/2磷酸化,和细胞增殖。[7]Fulvestrant作用于鸡胚绒毛尿囊膜还具有抗血管生成的作用效果。[8]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
+ 展开
  • Cell lines: MCF-7 乳腺癌细胞
  • Concentrations: 2.9 nM
  • Incubation Time: 5 天
  • Method: MCF-7细胞培养在多孔板中(24孔,按4 × 104密度为接种),孔中含基本必需培养基,培养基中包含酚红,胰岛素(10 μg/mL),和5%活性炭处理的胎牛血清,不含额外的雌二醇。接种2天后,在新鲜的培养基中加入Fulvestrant 和/或雌二醇。培养持续5天,且进一步改变培养基,通过在实验处理开始和结束测量全部细胞蛋白,且与只用乙醇(0.1%)处理的对照组进行比较后,测评生长状况。
    (Only for Reference)
动物实验:[6]
+ 展开
  • Animal Models: 携带人类乳腺癌移植瘤MCF-7的裸鼠
  • Formulation: 50 mg/mL 花生油
  • Dosages: 5 mg
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (164.8 mM)
Ethanol 100 mg/mL warmed (164.8 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品:
5% DMSO+95% Corn oil
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 606.77
化学式

C32H47F5O3S

CAS号 129453-61-8
稳定性 powder
别名 ICI-182780, ZD 9238

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01797120 Active, not recruiting Metastatic Breast Cancer PrECOG, LLC.|Novartis May 31, 2013 Phase 2
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT03024580 Not yet recruiting Breast Neoplasm Instituto Nacional de Cancer, Brazil|Cancer Research UK Cambridge Institute March 2017 Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3
NCT02983604 Recruiting Advanced Estrogen Receptor Positive HER2- Breast Cancer Gilead Sciences January 2017 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • 回答:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

相关Estrogen/progestogen Receptor产品

Tags: 购买Fulvestrant | Fulvestrant ic50 | Fulvestrant价格 | Fulvestrant DMSO溶解度 | 采购Fulvestrant | Fulvestrant生产 | Fulvestrant 小鼠 | Fulvestrant化学结构 | Fulvestrant分子量 | Fulvestrant molecular weight | Fulvestrant说明书 | Fulvestrant供应商 | Fulvestrant体内 | Fulvestrant细胞系 | Fulvestrant浓度 | Fulvestrant nmr | Fulvestrant核磁 | Fulvestrant半数抑制浓度 | Fulvestrant体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID